These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 78081)

  • 21. High incidence of adriamycin cardiotoxicity in children even at low cumulative doses: role of radionuclide cardiac angiography.
    Agarwala S; Kumar R; Bhatnagar V; Bajpai M; Gupta DK; Mitra DK
    J Pediatr Surg; 2000 Dec; 35(12):1786-9. PubMed ID: 11101737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of the left ventricular ejection fraction response to doxorubicin using a multiple linear regression model.
    Rabinovitch M; Suissa S; Stern J; Adam J; Mettauer B; Boileau G; Elstein J; Rouleau J
    Can J Cardiol; 1989; 5(8):382-8. PubMed ID: 2605548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antimyosin positivity in doxorubicin cardiotoxicity: earlier than the conventional evidence.
    Narula J; Strauss HW; Khaw BA
    J Nucl Med; 1993 Sep; 34(9):1507-9. PubMed ID: 8355071
    [No Abstract]   [Full Text] [Related]  

  • 24. Sexual dimorphism of doxorubicin-mediated cardiotoxicity: potential role of energy metabolism remodeling.
    Moulin M; Piquereau J; Mateo P; Fortin D; Rucker-Martin C; Gressette M; Lefebvre F; Gresikova M; Solgadi A; Veksler V; Garnier A; Ventura-Clapier R
    Circ Heart Fail; 2015 Jan; 8(1):98-108. PubMed ID: 25420486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiotoxicity of cancer chemotherapy in clinical practice.
    Jain D; Aronow W
    Hosp Pract (1995); 2019 Feb; 47(1):6-15. PubMed ID: 30270693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-invasive monitoring of cardiac hemodynamic parameters in doxorubicin-treated patients: comparison with echocardiography.
    Villani F; Meazza R; Materazzo C
    Anticancer Res; 2006; 26(1B):797-801. PubMed ID: 16739356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Doxorubicin cardiotoxicity in children: reduced incidence of cardiac dysfunction associated with continuous-infusion schedules.
    Berrak SG; Ewer MS; Jaffe N; Pearson P; Ried H; Zietz HA; Benjamin RS
    Oncol Rep; 2001; 8(3):611-4. PubMed ID: 11295089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dosing time dependency of doxorubicin-induced cardiotoxicity and bone marrow toxicity in rats.
    To H; Ohdo S; Shin M; Uchimaru H; Yukawa E; Higuchi S; Fujimura A; Kobayashi E
    J Pharm Pharmacol; 2003 Jun; 55(6):803-10. PubMed ID: 12841941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. α-Linolenic acid attenuates doxorubicin-induced cardiotoxicity in rats through suppression of oxidative stress and apoptosis.
    Yu X; Cui L; Zhang Z; Zhao Q; Li S
    Acta Biochim Biophys Sin (Shanghai); 2013 Oct; 45(10):817-26. PubMed ID: 23896563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Doxorubicin-induced cardiomyopathy.
    Otero FJ; Boor PJ; Sheahan RG
    Am J Med Sci; 2000 Jul; 320(1):59-63. PubMed ID: 10910374
    [No Abstract]   [Full Text] [Related]  

  • 31. Monitoring cardiac function in patients receiving doxorubicin.
    Lu P
    Semin Nucl Med; 2005 Jul; 35(3):197-201. PubMed ID: 16098293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of doxorubicin-induced congestive heart failure by continuous intravenous infusion in multiple myeloma; a case report and review of the literature.
    Lieverse RJ; Ossenkoppele GJ
    Neth J Med; 1991 Feb; 38(1-2):33-4. PubMed ID: 2030807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.
    Ewer MS; Vooletich MT; Durand JB; Woods ML; Davis JR; Valero V; Lenihan DJ
    J Clin Oncol; 2005 Nov; 23(31):7820-6. PubMed ID: 16258084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Late cardiotoxicity after treatment for a malignant bone tumor.
    Postma A; Bink-Boelkens MT; Beaufort-Krol GC; Kengen RA; Elzenga NJ; Schasfoort-van Leeuwen MJ; Schraffordt koops H; Kamps WA
    Med Pediatr Oncol; 1996 Apr; 26(4):230-7. PubMed ID: 8600333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Cardiotoxicity of doxorubicin in children].
    Pilon JW; Naeff MS; Taminiau JA
    Ned Tijdschr Geneeskd; 1984 Jul; 128(28):1339-43. PubMed ID: 6482993
    [No Abstract]   [Full Text] [Related]  

  • 36. [Efficacy of cardiac monitoring with echocardiography in adult patients receiving adriamycin].
    Okada Y; Sano M
    Gan To Kagaku Ryoho; 2003 Jun; 30(6):823-7. PubMed ID: 12852350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
    Chia S; Clemons M; Martin LA; Rodgers A; Gelmon K; Pond GR; Panasci L
    J Clin Oncol; 2006 Jun; 24(18):2773-8. PubMed ID: 16682726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
    Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
    J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
    Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
    Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adriamycin and the heart.
    Henderson IC; Frei TE
    N Engl J Med; 1979 Feb; 300(6):310-2. PubMed ID: 759884
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.